Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The US Department of Health and Human Services (HHS) has decertified Network for Hope, the federally funded organ procurement organization (OPO), which serves Kentucky and parts of Ohio, and West Virginia.

HHS officials cited "persistent safety failures" that could undermine public trust in organ transplantation as the reason for their move.

The move comes after months-long federal investigation into cases where organ recovery procedures were initiated despite patients showing signs of life.

The announcement marks one of the most significant federal actions against an organ procurement organization in recent years. It comes amid a bigger overhaul of the US organ transplant system.

"We're taking action because one bad apple can undermine trust in the entire transplant system," US Health Secretary Robert F. Kennedy Jr. said while announcing the proposed decertification, adding that patient safety and trust must remain the highest priority.

Why Was The Investigation Triggered?

The investigation stems from a widely reported 2021 case involving a Kentucky man who was being evaluated for organ donation after a drug overdose.

According to federal officials, preparations for organ retrieval continued even though the patient reportedly began showing neurological signs suggesting he was regaining consciousness. The procedure was ultimately halted, and the man survived.

Following that incident, the Health Resources and Services Administration (HRSA) reviewed 351 cases in which organ donation had been authorized but not completed.

Also read: Dr. Erica Schwartz Confirmed As CDC’s First Permanent Director In Nearly A Year

Federal investigators found:

• 103 cases showed concerning features.
• 73 patients displayed neurological signs considered incompatible with organ donation.
• At least 28 patients may not have been deceased when organ procurement activities began, raising serious ethical and legal concerns.

Investigators also pointed out ineffective neurological examinations, inadequate coordination between hospitals and procurement teams, questionable consent practices, and inconsistencies and errors in determining causes of death, particularly in cases of deaths due to overdose.

Push-Back From Network For Hope

Also read: Surgeon Barred From Practice After Connecting Wrong Parts of Patient’s Bowels During Emergency Surgery

Network for Hope has rejected the allegations and said it plans to appeal the proposed decertification.

In a statement, the organization said it "strongly disagrees" with the decision and maintains that it follows federal policies governing organ donation.

It also said that it has already introduced additional safeguards and strict policies, including instructing staff to stop organ donation procedures if ethical and legal concerns arise.

Public Confidence In Organ Donation

Most importantly, OPOs have no authority to declare death. That decision is made independently by hospital physicians before any organ recovery process can begin.

Most organ donations occur after brain death or circulatory death under strict medical protocols.

Earlier investigations into the Kentucky cases caused led to removing themselves from organ donor registries, raising concerns that safety controversies could reduce the availability of organs for patients awaiting transplantation.

Currently, more than 100,000 Americans are currently waiting for a life-saving organ transplant, with kidneys accounting for the majority of the demand. While organ donation remains one of the most effective ways to save lives, public confidence is essential to keeping donor registrations high.

The U.S. Senate has confirmed Dr. Erica Schwartz as the next Director of the U.S. Centers for Disease Control and Prevention (CDC), making her the public health agency's first permanent leader in nearly a year after months of uncertainty. The Senate approved her nomination in a 51-44 vote on August 5.

President Donald Trump nominated Schwartz in April, calling her "incredibly talented." During her confirmation hearing, she pledged to lead the CDC with transparency and scientific integrity.

She succeeds acting CDC Director Dr. Jay Bhattacharya, who had been leading the agency since February.

"I will lead with transparency, scientific integrity and accountability," Schwartz told senators during her confirmation hearing.

Schwartz, a physician, lawyer and former U.S. Deputy Surgeon General has an extensive background in medicine.

She takes charge of the CDC at a time when it is battling multiple outbreaks, staff shortages and growing scrutiny and uncertainty over its scientific independence.

Why Dr. Erica Schwartz's Appointment Is Key?

The agency has also undergone major workforce reductions while responding to several public health challenges, including a resurgence of measles, foodborne illness outbreaks and international infectious disease threats.

Schwartz's appointment is expected to bring stability to an agency that plays a central role in tracking disease outbreaks, issuing vaccination recommendations, responding to health emergencies and guiding public health policy in the US.

Also read: US Measles Cases Reach 2,371; RFK Jr Takes U-Turn, Urges Families to Vaccinate Kids

Who is Dr. Erica Schwartz?

Schwartz obtained her medical degree from Brown University and also holds a Master of Public Health and a law degree. She served in the U.S. Navy before joining the U.S. Public Health Service, where she later became Deputy Surgeon General during President Trump's first administration.

She has also served as Chief Medical Officer of the U.S. Coast Guard and most recently held leadership positions in the private healthcare sector.

Her confirmation comes as public health experts closely watch how the CDC balances scientific decision-making with increasing political scrutiny.

Many believe her appointment will be critical in rebuilding confidence in one of the world's most influential public health agencies.

Also read: One In Three Hospital Patients With Serious Mould Infections Died, CDC Study Finds

Erica Schwartz Backs Vaccines, Calls for Autism Research

Dr. Erica Schwartz is President Donald Trump's third CDC nominee in less than two years.

Schwartz ha pledged to restore public trust in the CDC through transparency and evidence-based decision-making during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions (HELP).

Throughout her nomination hearing, Schwartz repeatedly expressed support for vaccines, including mRNA COVID-19 vaccines, and strongly endorsed vitamin K injections for newborns to prevent life-threatening bleeding.

Although she also acknowledged that scientific evidence does not support that vaccines cause autism, she argued that more research is needed to better understand the rising cases of autism.

"We owe it to the American people to figure out why one in 30 children now has autism," she said.

Schwartz stated that she did not believe either President Trump or Health Secretary Kennedy would ask her to take actions that would harm public health or violate the law.

Amid rising global infertility rates, a new study has found that an imbalance in the bacteria present in men's semen may reduce a couple's chances of having a baby and increase the risk of pregnancy loss. Researchers also found that the composition of women's gut bacteria may influence fertility outcomes.

The study, published in The Lancet Obstetrics, Gynaecology & Women's Health, found these associations were particularly evident among couples undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), as well as those with a history of recurrent pregnancy loss.

Researchers from the University of Copenhagen, Denmark, said the findings point to "imbalances in men's semen and in women's gut bacteria as previously overlooked and potentially treatable risk factors for infertility and recurrent pregnancy loss."

Although the vaginal microbiome has been studied extensively in relation to fertility, the gut and seminal microbiomes have been largely overlooked.

“Incorporation of couple-level microbial assessment might represent a novel approach for targeted therapeutic strategies,” the team said.

Key Findings

The researchers followed 353 women and 191 of their male partners between April 2018 and September 2023. All participants were heterosexual couples undergoing fertility treatment or had experienced recurrent pregnancy loss.

They analyzed bacterial communities in the women's gut and vagina and in the men's semen before tracking pregnancies and birth outcomes. About one in four men had an unhealthy bacterial imbalance, known as dysbiosis, in their semen.

Among couples undergoing IVF or ICSI:

• 57% of couples in which the male partner had semen dysbiosis had a live birth.

• In comparison, 85% of couples without the imbalance went on to have a baby.

• Pregnancy loss was also more common when the male partner had semen dysbiosis, affecting roughly one in five more couples than those without the imbalance.

The researchers also noted that standard semen analysis cannot detect this bacterial imbalance, meaning a man's test results may appear normal even when dysbiosis is present.

Women's Gut Bacteria Also Affected Fertility

The study found that an imbalance in women's gut bacteria was associated with:

• A lower likelihood of becoming pregnant through fertility treatment.

• A longer time to conceive.

However, gut bacterial imbalance was not associated with miscarriage, while an imbalance in vaginal bacteria showed no clear link with either infertility or pregnancy loss.

What the Findings Mean

According to the researchers, assessing the microbiome in both men and women could improve infertility evaluation and help identify previously overlooked, potentially treatable factors affecting fertility.

They added that, if confirmed in larger studies, therapies aimed at restoring healthy bacterial balance in semen and the gut could improve fertility outcomes and reduce recurrent pregnancy loss.

What Is Infertility?

Infertility is a disease of the male or female reproductive system, defined as the inability to achieve pregnancy after 12 months or more of regular, unprotected sexual intercourse.

According to the World Health Organization (WHO), one in six people globally experience infertility during their lifetime. The condition can cause significant emotional distress, social stigma and financial hardship, with far-reaching effects on mental and psychosocial well-being.